STOCK TITAN

Monopar Therapeutics Inc - MNPR STOCK NEWS

Welcome to our dedicated news page for Monopar Therapeutics (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Monopar Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Monopar Therapeutics's position in the market.

Rhea-AI Summary
Monopar Therapeutics to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences
-
Rhea-AI Summary
Monopar Therapeutics Inc. announces encouraging results from the Phase 1b trial of Camsirubicin, with tumor size reductions in patients. MNPR-101 radiopharma program is progressing towards first-in-human studies. Second quarter 2023 financial results show a net loss of $2.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
-
Rhea-AI Summary
Monopar Therapeutics provides positive update on Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Tumor size reductions of 18% and 20% observed in patients at 650 mg/m2 dose level. Dose-response hypothesis supported. No drug-related cardiotoxicity observed. Hair loss and oral mucositis rates lower compared to doxorubicin. Phase 2 trial planned with GEIS collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.23%
Tags
Rhea-AI Summary
Monopar Therapeutics Inc. has announced a collaboration with the Cancer Science Institute of Singapore to evaluate radiopharmaceutical versions of MNPR-101 in aggressive cancers. Dr. Anand Jeyasekharan will be the Principal Investigator on the collaboration. The collaboration aims to identify high uPAR expressing cancers and explore the use of radiolabeled MNPR-101 for clinical imaging and potential therapeutic options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
conferences
Rhea-AI Summary
Monopar Therapeutics provides an update on its Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). One patient in the trial achieved tumor shrinkage and had the tumor resected. All patients in the 520 mg/m2 cohort achieved stable disease. The Phase 1b data show an improvement in median progression-free survival compared to previous trials. No drug-related cardiotoxicity has been observed. Monopar has a clinical collaboration agreement with GEIS for a Phase 2 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.34%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.34%
Tags
Monopar Therapeutics Inc

Nasdaq:MNPR

MNPR Rankings

MNPR Stock Data

13.63M
8.31M
52.35%
1.55%
0.98%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Wilmette

About MNPR

monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.